Effects of Glaucoma Medication on Dry Eye Syndrome and Quality of Life in Patients with Glaucoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To investigate ocular surface diseases and changes in the quality of life of patients using glaucoma medications. Methods: Participants were divided into the normal (31 individuals, 62 eyes) and glaucoma medication (30 patients, 60 eyes)groups. Changes in tear break-up time, lipid layer thickness (LLT), corneal and conjunctival staining scores, ocular surface diseaseindex (OSDI), and Visual Function Questionnaire 25 (VFQ-25) score were assessed for 1 year. Results: The change in mean LLT was lower in glaucomatous eyes than in control eyes (p = 0.019) after 1 year. The resultsof OSDI deteriorated (p’ = 0.008), but conjunctival staining and Schirmer test results showed improvement in glaucomatouseyes compared to those in control eyes (p’ =0.035 and 0.009, respectively). The average LLT decreased at 6 and 12 months,but there was no change at 24 months. In pairwise analysis, the decrease in LLT over the first 6 months was statistically significant(p < 0.001) and remained unchanged until 24 months. Among the VFQ items, scores for near activity and social functiondeteriorated over 1 year in the medication group (p’ = 0.033 and 0.015, respectively). However, there was no difference inthe total VFQ score. Conclusions: Significant reduction in LLT and deterioration of OSDI were observed in the medication group compared to thecontrol group. However, this deterioration was observed only in the first 6 months. There was no significant difference in theVFQ total score. Nonetheless, there were significant differences in near activity and social function between the control andmedication groups. Therefore, the results of this study showed that although glaucoma medication worsened eye dryness,the change was limited and did not worsen the quality of life. Glaucoma medication should be used with the considerationthat they can limit near activity and social functioning.
Abstract
Purpose: To investigate ocular surface diseases and changes in the quality of life of patients using glaucoma medications. Methods: Participants were divided into the normal (31 individuals, 62 eyes) and glaucoma medication (30 patients, 60 eyes)groups. Changes in tear break-up time, lipid layer thickness (LLT), corneal and conjunctival staining scores, ocular surface diseaseindex (OSDI), and Visual Function Questionnaire 25 (VFQ-25) score were assessed for 1 year. Results: The change in mean LLT was lower in glaucomatous eyes than in control eyes (p = 0.019) after 1 year. The resultsof OSDI deteriorated (p’ = 0.008), but conjunctival staining and Schirmer test results showed improvement in glaucomatouseyes compared to those in control eyes (p’ =0.035 and 0.009, respectively). The average LLT decreased at 6 and 12 months,but there was no change at 24 months. In pairwise analysis, the decrease in LLT over the first 6 months was statistically significant(p < 0.001) and remained unchanged until 24 months. Among the VFQ items, scores for near activity and social functiondeteriorated over 1 year in the medication group (p’ = 0.033 and 0.015, respectively). However, there was no difference inthe total VFQ score. Conclusions: Significant reduction in LLT and deterioration of OSDI were observed in the medication group compared to thecontrol group. However, this deterioration was observed only in the first 6 months. There was no significant difference in theVFQ total score. Nonetheless, there were significant differences in near activity and social function between the control andmedication groups. Therefore, the results of this study showed that although glaucoma medication worsened eye dryness,the change was limited and did not worsen the quality of life. Glaucoma medication should be used with the considerationthat they can limit near activity and social functioning.
참고문헌 (22)
- Actis AG, "Ocular surface alterations and topical antiglaucomatous therapy: a review", Open Ophthalmol J, 8, pp.67~72 (2014)
- Kastelan S, "How ocular surface disease impacts the glaucoma treatment outcome", Biomed Res Int, 2013, pp.696328~ (2013)
- Zhang X, "Ocular surface disease and glaucoma medications: a clinical approach", Eye Contact Lens, 45, pp.11~18 (2019)
- Camp A, "Dry eye specific quality of life in veterans using glaucoma drops", Cont Lens Anterior Eye, 38, pp.220~225 (2015)
- Stringham J, "Barriers to glaucoma medication compliance among veterans: dry eye symptoms and anxiety disorders", Eye Contact Lens, 44, pp.50~54 (2018)
- Rossi GC, "Dry eye syndrome-related quality of life in glaucoma patients", Eur J Ophthalmol, 19, pp.572~579 (2009)
- AlDarrab A, "Functional visual ability and quality of life in children with glaucoma", Am J Ophthalmol, 200, pp.95~99 (2019)
- Lee SY, "Tear lipid layer thickness change and topical anti-glaucoma medication use", Optom Vis Sci, 93, pp.1210~1217 (2016)
- Tomlinson A, "The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee", Invest Ophthalmol Vis Sci, 52, pp.2006~2049 (2011)
- Janetos TM, "Geographic and provider variations in ocular hypotensive medication claims among Medicare part D enrollees", J Glaucoma, 28, pp.e29~e33 (2019)
- Seo SJ, "Estimated prevalence of glaucoma in South Korea using the National Claims Database", J Ophthalmol, 2016, pp.1690256~ (2016)
- Isreb MA, "Correlation of lipid layer thickness measurements with fluorescein tear film break-up time and Schirmer’s test", Eye (Lond), 17, pp.79~83 (2003)
- Guarnieri A, "Relationship between OSDI questionnaire and ocular surface changes in glaucomatous patients", Int Ophthalmol, 40, pp.741~751 (2020)
- Leung EW, "Prevalence of ocular surface disease in glaucoma patients", J Glaucoma, 17, pp.350~355 (2008)
- Park J, "Functional and structural evaluation of the meibomian gland using a LipiView interferometer in thyroid eye disease", Can J Ophthalmol, 53, pp.373~379 (2018)
- Markoulli M, "Imaging the tear film: a comparison between the subjective Keeler Tearscope-Plus and the objective Oculus Keratograph 5M and LipiView interferometer", Curr Eye Res, 43, pp.155~162 (2018)
- Spaeth G, "Evaluation of quality of life for patients with glaucoma", Am J Ophthalmol, 141(1 Suppl), pp.S3~S14 (2006)
- Lee SM, "Effect of topical glaucoma medication on tear lipid layer thickness in patients with unilateral glaucoma", Indian J Ophthalmol, 67, pp.1297~1302 (2019)
- Ramli N, "Ocular surface disease in glaucoma: effect of polypharmacy and preservatives", Optom Vis Sci, 92, pp.e222~e226 (2015)
- Arita R, "Comparison of the longterm effects of various topical antiglaucoma medications on meibomian glands", Cornea, 31, pp.1229~1234 (2012)
- Arita R, "Increased tear fluid production as a compensatory response to meibomian gland loss: a multicenter cross-sectional study", Ophthalmology, 122, pp.925~933 (2015)
- Perez-Bartolome F, "Ocular surface disease in patients under topical treatment for glaucoma", Eur J Ophthalmol, 27, pp.694~704 (2017)